Navigation Links
A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer

A recent study has shown that a chemotherapy regimen combining vinorelbine (Navelbine) and mitoxantrone (Novantrone)// with the corticosteroid prednisone is effective in the treatment of hormone-refractory prostate cancer . Specialists say this treatment should be offered to symptomatic patients earlier in their disease.

However researchers added that a larger phase 2 study of this treatment regimen is planned. From a group of 66 patients who had advanced prostate cancer, the investigators recruited 12 for whom previous hormone therapy had failed in at least 3 lines of treatment.

The investigators included patients who had undergone palliative radiotherapy at any point during their disease. The patient’s median age was 67 years, with a range of 60 to 81 years. The patient’s median Eastern Cooperative Oncology Group performance status was 1, with a range of 0 to 2. All the patients had bone metastases, some with multiple sites. One patient had lymph node metastasis, and 1 had visceral disease. Three patients had significant ischaemic heart disease.

Each treatment cycle consisted of 10 to 12 mg/m2 of mitoxantrone on day 1, followed by 20 mg/m2 of vinorelbine on days 1 through 8. This cycle was repeated every 3 weeks. The patients also received 12.5 mg daily of prednisone. A total of 95 cycles were given, with a median of 7 cycles per patient and a range of 5 to 9 cycles per patient. Two patients repeated the treatment at 6 months and 12 months after the initial treatment. Among these patients, 50% had a marked decrease in pain and improvement in ECOG performance status, according to specialists. In 8 cycles, due to the response to treatment, the dose of vinorelbine was reduced 50% and in 4 cycles it was reduced 75%. The mitoxantrone dose was reduced 50% in 5 cycles. Although 1 patient had a drop in prostate specific antigen (PSA) of more than 50%, the computed tomography findings did not show an equivalent response.

The patients' median time to progression was 10 months, with a range of 6 months to over 20 months. Two patients are living; 8 died due to disease progression; and 2 died of other causes. The toxicity episodes consisted of 6 neutropaenic events, all afebrile. Otherwise, the investigators documented no Grade 4 haematological toxicity and no non-haematological toxicity.
'"/>




Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Drug Combinations May Boost Stroke Risk
3. Combination therapy to treat breast cancer
4. Combination regime may work against prostate cancer
5. Smoking and Breast Cancer - A Deadly Combination
6. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
7. Combination Therapy Effective In Improving Lung Cancer Survival
8. Combination Therapy Found To Improves Stroke Recovery
9. Combination Therapy Found To Be More Effective In Treating Brain Cancer
10. Combination of Clopidogrel-aspirin is better for preventing stroke than only aspirin
11. New Combination Therapy Option for HIV Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... Bragdon to its Department of Orthopedic Surgery, Division of Hand, Upper Extremity and ... orthopedic surgery. She is board-certified in both Orthopedics and Hand Surgery. ...
(Date:3/22/2017)... NJ (PRWEB) , ... March 22, 2017 , ... ... firm that serves communities throughout north Jersey and the New York metropolitan region, ... to provide regional support for homeless families. , At present, more than two ...
(Date:3/22/2017)... ... 22, 2017 , ... The Jim Shortridge Agency, an Oklahoma ... owners, is joining the Teen Recovery Solutions organization in a charity event intended ... number of Oklahoma teens and adolescents face problems from drugs, alcohol, abuse, and ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... services and financial planning assistance to communities throughout central Ohio, is initiating a ... , Estimates from the Department of Defense and the Veteran's Brain Injury Center ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... guarantee patient payments for providers while creating a positive patient experience. , ... that further educates and empowers patients by helping them understand their financial responsibility. ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 22, 2017 Hologic, Inc. (Nasdaq: ... acquisition of Cynosure, Inc., a leader in medical aesthetics ... "We are pleased to complete our acquisition ... Michael Davin and the entire Cynosure team to ... medical aesthetics market," said Steve MacMillan , Hologic,s ...
(Date:3/22/2017)... 22, 2017 FinancialBuzz.com News Commentary ... rapidly due to the significant development and innovation in ... Market Research, the global electrophysiology market was worth $3.42 ... billion by 2022, with a GAGR of 13.4%. Electrophysiology ... diagnose abnormal heartbeats or arrhythmia. The report indicates that ...
(Date:3/22/2017)...  As the world,s leading non-profit dedicated to fighting ... played a role in most therapies used today to ... helping patients with other cancers and serious diseases. Such ... cutting-edge research – more than $1 billion in the ... record-breaking sum of $4.1 million raised at the 30 ...
Breaking Medicine Technology: